Eucrisa Ointment
NDC Package 55724-211-23

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Eucrisa (crisaborole) ointment is a medication used to treat eczema. This formulation utilizes a ointment delivery system. Marketed by Pfizer Laboratories Div Pfizer Inc, this product is identified by NDC 55724-211 and is authorized under FDA application NDA207695.

Identification & Billing

NDC Package Code
55724-211-23
Package Description
1 TUBE in 1 CARTON / 60 g in 1 TUBE
Product Code
55724-211
11-Digit Billing Format
55724021123
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Eucrisa
Non-Proprietary Name
Crisaborole
Substance Name
Crisaborole
Dosage Form
Ointment - A semisolid3 dosage form, usually containing <20% water and volatiles5 and >50% hydrocarbons, waxes, or polyols as the vehicle. This dosage form is generally for external application to the skin or mucous membranes.
Administration Route
Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
Active Ingredient(s)
CRISABOROLE 20 mg/g
Pharmacologic Class
Usage Information
This medication is used to treat eczema. It reduces swelling, redness, and itching on the skin.

Regulatory & Marketing

Labeler Name
Pfizer Laboratories Div Pfizer Inc
Product Type
Human Prescription Drug
FDA Application #
NDA207695
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
01-30-2017
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (55724-211). Click a package code to view its specific billing and regulatory data.

55724-211-11
1 TUBE in 1 CARTON / 100 g in 1 TUBE
55724-211-21
1 TUBE in 1 CARTON / 60 g in 1 TUBE
55724-211-42
6 TUBE in 1 CARTON / 2.5 g in 1 TUBE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 55724-211-23 identifies a specific commercial package of 1 tube in 1 carton / 60 g in 1 tube of Eucrisa, a human prescription drug labeled by Pfizer Laboratories Div Pfizer Inc. This ointment is formulated for topical use and contains crisaborole as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Pfizer Laboratories Div Pfizer Inc on January 30, 2017. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used to treat eczema. It reduces swelling, redness, and itching on the skin.

How is this Pfizer Laboratories Div Pfizer Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 55724021123. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
55724-211-23
11-Digit CMS (5-4-2)
55724-0211-23

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.